RT Journal Article
T1 Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
A1 Pineda, J. A.
A1 Morano-Amado, L. E.
A1 Granados, R.
A1 Macias, J.
A1 Tellez, F.
A1 Garcia-Deltoro, M.
A1 Rios, M. J.
A1 Collado, A.
A1 Delgado-Fernandez, M.
A1 Suarez-Santamaria, M.
A1 Serrano, M.
A1 Miralles-Alvarez, C.
A1 Neukam, K.
A1 Sociedad Espanola Enfermedades, 
A1 Sociedad Andaluza Enfermedades, 
K1 Cirrhosis
K1 Direct-acting antivirals
K1 Hepatitis C virus genotype 3
K1 Interferon-free regimens
K1 Sustained virological response
K1 Viral kinetics
K1 Phase-iii
K1 Sofosbuvir
K1 Hcv
K1 Velpatasvir
K1 Daclatasvir
K1 Ribavirin
AB Objective: The aim of this study was to determine the predictive capacity of response at treatment week (TW) 4 for the achievement of sustained virological response 12 weeks after the scheduled end of therapy date (SVR12) to treatment against hepatitis C virus (HCV) genotype 3 (GT3) infection with all-oral direct-acting antiviral (DAA) -based regimens.Patients and methods: From a prospective multicohort study, HCV GT3-infected patients who completed a course of currently recommended DAA-based therapy at 33 Spanish hospitals and who had reached the SVR12 evaluation time-point were selected. TW4 HCV-RNA levels were categorized as target-notdetected (TND), below the lower limit of quantification (LLOQTD) and >= LLOQ.Results: A total of 123 patients were included, 86 (70%) received sofosbuvir/ daclatasvir +/- ribavirin, 27 (22%) received sofosbuvir/ ledipasvir/ ribavirin and 10 (8.1%) received sofosbuvir/ ribavirin, respectively. In all, 114 (92.7%) of the 123 patients presented SVR12 in an on-treatment approach, but nine (7.3%) patients relapsed, all of them had presented cirrhosis at baseline. In those who achieved TND, LLOQTD and >= LLOQ, SVR12 was observed in 81/83 (98%; 95% CI 91.5%-99.7%), 24/28 (85.7%; 95% CI 67.3%-96%) and 9/12 (75%; 95% CI 42.8%-94.5%), respectively; p(linear association) 0.001. Corresponding numbers for subjects with cirrhosis were: 52/54 (96.3%; 95% CI 87.3%-95.5%), 14/ 18 (77.8%; 95% CI 52.4%-93.6%) and 7/10 (70%; 95% CI 34.8%-93.3%); p 0.004.Conclusions: TW4-response indicates the probability of achieving SVR12 to currently used DAA-based therapy in HCV genotype 3-infected individuals with cirrhosis. This finding may be useful to tailor treatment strategy in this setting. (C) 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
PB Elsevier sci ltd
SN 1198-743X
YR 2017
FD 2017-06-01
LK http://hdl.handle.net/10668/18752
UL http://hdl.handle.net/10668/18752
LA en
DS RISalud
RD Apr 19, 2025